Lonza revs for GSK clinical supplies

GlaxoSmithKline will be relying on Lonza for clinical supplies of early stage drugs in a relationship that has longer term implications. The contract manufacturer says it will produce five of GSK's monoclonal antibody candidates and will help the drug giant plan for the construction of its own biopharma plant in Britain.

The drug candidates are currently in Phase I and Phase II testing, reports Reuters, which notes that the deal is a welcome sign for CMOs. Cost-focused drugmakers have cut back on their outsourcing, and their thinning of inventories amounts to a double blow to the contractors.

GSK announced plans late last year to build a biotech facility and expand an existing plant in the U.K. The announcement followed a British government promise to cut corporation taxes for patent-derived income.

- see the article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.